Skip to content

Gemini on Cancer Detection

The Multi-Cancer Early Detection (MCED) and liquid biopsy landscape has evolved rapidly beyond GRAIL's Galleri test. While GRAIL popularized the use of cell-free DNA (cfDNA) methylation, competing companies are trying to improve early-stage sensitivity by using multiomics (combining methylation with fragmentomics, proteins, or RNA) or using buffy-coat samples as a filtering mechanism to eliminate false positives.

A breakdown of the prominent companies, their platforms, and the specific analytes they leverage reveals several distinct approaches:

1. Multiomic & Methylation-Focused Competitors (cfDNA)

These platforms compete directly in the MCED space, utilizing advanced sequencing techniques and machine learning to analyze plasma-derived cfDNA.

  • Exact Sciences (Cancerguard®): Developed in collaboration with the Mayo Clinic, the Cancerguard test targets the deadliest cancers (including pancreatic, lung, liver, and esophageal). Rather than relying solely on methylation, Exact Sciences uses a multiomic approach that combines cfDNA methylation, mutation data, and protein biomarkers to maximize sensitivity while keeping false-positive rates low.
  • Adela: Adela utilizes a proprietary genome-wide methylome enrichment technology (cfMeDIP-seq). Unlike GRAIL, which relies on chemical bisulfite conversion—a process that can degrade fragile cfDNA—Adela uses an affinity-based enrichment method to capture highly detailed methylation signals without destroying the underlying DNA fragments. They target both multi-cancer early detection and Molecular Residual Disease (MRD) monitoring.
  • Freenome: Freenome emphasizes that a single analyte cannot completely capture tumor heterogeneity. Their platform evaluates signals along the entire central dogma: cfDNA fragments (fragmentomics), methylation patterns, cell-free RNA (cfRNA), and circulating proteins, alongside immune-profiling. They have collaborated with NVIDIA to build open-source deep learning foundation models trained to decode these intricate cfDNA signatures.
  • Gene Solutions (SPOT-MAS 10): A prominent player in the Asian market that received an FDA Breakthrough Device Designation. It is a multi-omics test analyzing cfDNA methylation alongside fragmentomic signatures (analyzing the specific sizes and end-motifs of chopped-up DNA strands floating in the plasma) via machine learning to screen for 10 common and aggressive cancers.

2. The Role of the Buffy-Coat (White Blood Cells)

The buffy-coat layer of a centrifuged blood sample consists of white blood cells (leukocytes) and platelets. In early-detection liquid biopsies, buffy-coat is primarily utilized as a critical filter for biological noise, rather than a standalone analyte for finding tumor DNA.

The "CHIP" Problem: As humans age, stem cells in the bone marrow naturally acquire somatic mutations. This phenomenon is known as Clonal Hematopoiesis of Indeterminate Potential (CHIP). These mutated white blood cells shed their own mutated DNA into the bloodstream.

If a liquid biopsy assay relies purely on looking for cancer-associated mutations in cfDNA, it can easily mistake a harmless CHIP mutation for an early-stage solid tumor, resulting in a terrifying false positive.

  • Guardant Health (Guardant360 / Guardant Shield): Guardant routinely sequences the patient's buffy-coat alongside the plasma cfDNA. By matching the mutations found in the plasma against the genomic data found in the buffy-coat, their bioinformatics pipeline filters out mutations originating from normal blood cells, ensuring the reported mutations are genuinely tumor-derived.
  • Freenome & Exact Sciences: Both utilize germline DNA derived from white blood cells (buffy-coat) during their assay validation and clinical pipeline development to map out background noise and focus machine learning models exclusively on true malignancy signals.

3. Alternative Analytes & Niche Platforms

Other innovators are looking entirely outside of plasma cfDNA to capture early-stage cancer markers:

Company / Institution Primary Analyte(s) Methodology & Target
Lucence (LiquidHallmark) ctDNA Mutations + Amplicon NGS Uses ultrasensitive amplicon sequencing to look for highly specific cancer mutations across dozens of cancer types.
Thrive Early Detection (Acquired by Exact Sciences) cfDNA Mutations + Proteins Developed the "CancerSEEK" paradigm, utilizing a focused panel of DNA mutations coupled with specific protein driver markers.
Extracellular Vesicle Pioneers (Various Academic/Biotech Hubs) Exosomes / Extracellular Vesicles (EVs) Isolating lipid-bound vesicles shed by tumors. EVs contain protected cargo (mRNA, microRNA, and proteins) that directly reflect the cell of origin.
Delfi Diagnostics cfDNA Fragmentomics Uses low-coverage whole-genome sequencing to map the fragmentation patterns of cfDNA. Because tumor DNA is packaged differently than healthy DNA, its "breakage" patterns form a unique signature.